Synthesis, in vitro and in vivo pharmacological evaluation of serotoninergic ligands containing an isonicotinic nucleus

European Journal of Medicinal Chemistry
F FiorinoG Caliendo

Abstract

Isonicotinamide derivatives, linked to an arylpiperazine moiety, were prepared and their affinity to 5-HT1A, 5-HT2A and 5-HT2C receptors were evaluated. The combination of structural elements (heterocyclic nucleus, alkyl chain and 4-substituted piperazine) known to play critical roles in affinity for serotoninergic receptors and the proper selection of substituents led to compounds with high specificity and affinity towards serotoninergic receptors. In binding studies, several molecules showed high affinity in nanomolar and subnanomolar range at 5-HT1A, 5-HT2A and 5-HT2C receptors and moderate or no affinity for other relevant receptors (D1, D2, α1 and α2). N-(3-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)propyl)isonicotinamide (4s) with Ki = 0.130 nM, was the most active and selective derivative for the 5-HT1A receptor compared to other serotoninergic, dopaminergic and adrenergic receptors. Compound 4o, instead, showed 5-HT2A affinity values in subnamolar range. Moreover, the compounds having better affinity and selectivity binding profile towards 5-HT1A and 5-HT2A receptors were selected in order to be tested by in vitro and in vivo assays to determine their functional activity.

References

Dec 15, 1977·European Journal of Pharmacology·I CreeseS H Snyder
Dec 1, 1992·Brain Research Bulletin·J L MoreauW E Haefely
Aug 1, 1989·Pharmacology, Biochemistry, and Behavior·H H BerendsenC L Broekkamp
Jan 1, 1987·Psychopharmacology·R G Lister
Jul 25, 1995·European Journal of Pharmacology·E A ForsterA Fletcher
Sep 23, 1997·Pharmacology, Biochemistry, and Behavior·B J Cao, R J Rodgers
Feb 7, 1998·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M R BriejerJ A Schuurkes
Jan 12, 1999·Neuroscience and Biobehavioral Reviews·B OlivierK A Miczek
Aug 26, 1999·Neuropharmacology·N M Barnes, T Sharp
Jan 5, 2002·European Journal of Medicinal Chemistry·G CaliendoV Santagada
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Daniel HoyerGraeme R Martin
Apr 12, 2002·Current Medicinal Chemistry·M L López-RodríguezA Viso
Feb 7, 2003·Mini Reviews in Medicinal Chemistry·Hernán Pessoa-MahanaDavid C Pessoa-Mahana
Aug 27, 2005·European Journal of Medicinal Chemistry·Hanna ByrtusEwa Chojnacka-Wójcik
Feb 26, 2008·Bioorganic & Medicinal Chemistry·Matthew A ParkerDavid E Nichols
Mar 30, 2010·Bioorganic & Medicinal Chemistry Letters·Ferdinando FiorinoGiuseppe Caliendo
Dec 3, 2011·European Journal of Medicinal Chemistry·Ferdinando FiorinoGiuseppe Caliendo
Jun 23, 2015·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·D M Kendig, J R Grider
Jun 27, 2015·British Journal of Pharmacology·Michael J CurtisJohn C McGrath

❮ Previous
Next ❯

Citations

Mar 4, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sana YaqoobFarooq-Ahmad Khan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.